TIANJIN DEV Reports Fiscal Year Results: Profit Attributable to Owners Declines 21.92% to HK$428 Million

Stock News03-30

TIANJIN DEV (00882) announced its annual results for the period ending December 31, 2025. The group recorded revenue of HK$3.196 billion, a decrease of 4.86% compared to the previous year. Profit attributable to owners of the company was HK$428 million, down 21.92% year-on-year. Basic earnings per share were HK39.89 cents, and the board proposed a final dividend of HK8.82 cents per share.

According to the announcement, the pharmaceutical segment generated revenue of approximately HK$1.665 billion in 2025, an increase of 3.4% from HK$1.61 billion in the previous year. Within this segment, revenue from the production and sale of chemical drugs, proprietary Chinese medicines, and other healthcare products amounted to about HK$1.509 billion, up 3.7% from HK$1.455 billion a year earlier. Revenue from the sale of packaging materials reached approximately HK$156 million, a slight increase of 0.9% compared to HK$155 million in 2024.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment